Theradiag: Change in the Composition of the Board of Directors to Be Voted on at the Annual General Meeting of May 5, 2022
30 Marzo 2022 - 7:30AM
Business Wire
Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company
specializing in in vitro diagnostics and theranostics, today
announced that a change in the composition of its Board of
Directors will be put to the Annual General Meeting of May 5, 2022
for approval.
In order to allow shareholders to determine the future
composition of the Company’s Board of Directors, four members of
the Board, namely Mr. Pierre MORGON, Mr. Vincent FERT, Mr. Gejia
OUYANG and Mrs. Sylvie BRATEL, have tendered their resignation to
the Company effective at the end of the Annual General Meeting of
May 5, 2022 and simultaneously proposed submitting to that AGM
their appointment as Board members for a new term. Mr. Bertrand de
CASTELNAU’s mandate as a Board member expires at the end of said
Meeting, and the renewal of his appointment will therefore be
submitted to the Annual General Meeting of May 5, 2022 for
approval.
Moreover, following the acquisition of a stake in the Company by
Biosynex, which – at the current time and to the best of
Theradiag’s knowledge – holds 25.07% of its share capital, the
Annual General Meeting of May 5, 2022 will also be asked to approve
the appointment of Larry ABENSUR (CEO of Biosynex), Thomas LAMY
(Deputy Managing Director of Biosynex) and Thierry PAPER (Deputy
Managing Director of Biosynex) to the Board.
The term of office of the Board members appointed by the Annual
General Meeting will be three years.
Financial calendar: - Annual General Meeting,
Thursday May 5, 2022 - H1 2022 revenue, Monday July 18, 2022
- H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan. For more
information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220329005660/en/
Theradiag Bertrand de Castelnau CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mag 2023 a Mag 2024
